Back to search results

QXL138AM for Advanced Solid Tumors and Multiple Myeloma

This study is testing a new treatment called QXL138AM for people with advanced solid tumors (like ovarian, pancreatic, kidney, and liver cancer) or multiple myeloma. QXL138AM is an "immuno-cytokine," which means it combines an antibody (a protein that targets specific cells) with interferon alpha 2a (a protein that helps the immune system). The main goal is to see how safe QXL138AM is and what side effects it might cause. Researchers will also look at how the body handles the drug and if it shows any early signs of helping to treat the cancer. You might be able to join if you have one of these cancers and your current treatments are no longer working or are not an option. The study is currently open, but its exact status is unclear.

Study design
This is an open-label, first-in-human study, meaning everyone knows what treatment is being given. It will involve about 100 participants and is designed in two main parts to find the right dose and then expand to more patients.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety will be measured throughout the study, which is anticipated to last 3.5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06582017

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

Recruiting
PHASE1Ages 18+InterventionalTreatment
Nammi Therapeutics Inc
~100 participants
Updated 2026-08-27 on ClinicalTrials.gov
What's tested:QXL138AM Injection every 2 weeks by IV Infusion

At a glance

Recruiting sites
10 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Adverse Events
Measured over Throughout study - anticipated 3.5 years

Conditions

Ovarian Cancer
Pancreas Cancer
Urothelial Carcinoma
Renal Cell Carcinoma
Hepatocellular Carcinoma
Gastrointestinal Cancer
Lung Cancer
Prostate Cancer
Breast Cancer

Explore related trials

Breast CarcinomaHepatocellular CarcinomaLung CarcinomaMalignant Digestive System NeoplasmMalignant Ovarian NeoplasmMultiple MyelomaPancreatic CarcinomaProstate CarcinomaRenal Cell CarcinomaSolid NeoplasmUrothelial Carcinoma

Where it's being run

10 sites across 6 states
California4
New York2
Colorado1
Georgia1
Texas1
Wisconsin1

Study leadership

  • Dennis Kim, MD · STUDY_DIRECTOR · Nammi Therapeutics Inc

Who to contact

David Stover, PhD
[email protected]
818-926-3428
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histopathologically confirmed diagnosis of an advanced, unresectable, or metastatic solid tumor (ovarian, pancreatic, urothelial, renal, hepatocellular, gastrointestinal (GI), lung, prostate, and breast cancer).
Have progressed despite standard therapies, or for whom conventional therapy is not effective or tolerable, as judged by the Investigator. Patients must have no available therapeutic options known to confer clinical benefit for their tumor type. 2. Participants with Multiple Myeloma
Have progressed despite standard therapies, or for whom conventional therapy is not effective or tolerable, as judged by the Investigator.
Patients must have failed at least 3 prior therapies for myeloma and should have had prior exposure to a proteosome inhibitor, an IMiD, and an anti-CD38-directed therapy.
Have a negative serum pregnancy test at screening and a negative pregnancy test at Week 1 Day 1 prior to first dose of QXL138AM, AND
Agree to use at least 1 highly effective method of contraception for the duration of study participation, and for 120 days after last dose of QXL138AM.
Agree to use at least 1 highly effective method of contraception for the duration of study participation, and for 120 days after last dose of QXL138AM, AND
Refrain from sperm donation prior to the first dose of investigational product through 120 days following the last dose of QXL138AM.

What this trial measures

  • Incidence of Adverse EventsThroughout study - anticipated 3.5 years

    Record all safety events during study including AEs, SAEs, DLTs, AESIs.